down nirmatrelvir metabolism and therefore boosting its effect. It is taken bymouth. In unvaccinated high-risk people with COVID‑19, nirmatrelvir/ritonavir
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir
concentration. In December 2021, the combination of nirmatrelvir and ritonavir was granted emergency use authorization by the US Food and Drug Administration (FDA)
clarithromycin, verapamil, ketoconazole and anti-viral drugs, including nirmatrelvir and ritonavir. These medications should not be administered with triamcinolone